Details for New Drug Application (NDA): 211210
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
The generic ingredient in QMIIZ ODT is meloxicam. There are twenty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the meloxicam profile page.
Summary for 211210
Tradename: | QMIIZ ODT |
Applicant: | Tersera |
Ingredient: | meloxicam |
Patents: | 1 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 7.5MG | ||||
Approval Date: | Oct 19, 2018 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Aug 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 15MG | ||||
Approval Date: | Oct 19, 2018 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Aug 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription